Our annual Biobusiness Summer School is one of our most well established activities throughout the year. The first Biobusiness Summer School was held in 2014 and the event has only gained more popularity ever since. Each year, Synapse - Life Science Connect invites 50 ambitious and motivated students and recent graduates from numerous countries to participate. The summer school is a 5 day activity where industry experts within various fields such as marketing, regulatory affairs, finance accounting, intellectual property rights, consulting, strategy implementation, bio-entrepreneurship and much more come to share their knowledge and expertise. 

Our vision and goal with the Biobusiness Summer School is to inspire and inform our participants about the many different aspects of working in the biotech- and pharmaceutical industry. Furthermore we seek to engage our participants to develop important practical skills within the fields taught, which we believe will help them in their future careers.

Our 7th annual BioBusiness Summer School will this year take place on the 16th-20th of August.


There was a great variety of speakers coming from great companies and different backgrounds that make me engaged in the lectures and workshops.
Zulema Díaz, Associate Global Brand Manager at Lundbeck
Three years after the BioBusiness Summer School I've switched from being a scientist to become a consultant due to the first contact I was provided with BCG.
Motiejus Melynis, Consultant at Boston Consulting Group

Join us for five fantastic and educational days at the Synapse BioBusiness Summer School 2021. If you are a life science student interested in the business side of the industry and would like to know more about bio-entrepreneurship, IPR, finance, regulatory affairs and many other aspects of bio-business then the Synapse BioBusiness Summer School is perfect for you!

At some point in their career many life science students will work in the industry. Synapse – Life Science Connect is aiming to bridge the gap and give students a taste of the business side of the life science industry at our BioBusiness Summer School 2021. We will explore the different steps of company evolution and go into depths with the various elements of the business side of life science. Furthermore we will look at alternative career paths and how to manage your career as well as many other exciting topics.

Throughout the week our speakers will give inspirational lectures, interactive workshops and tailored case challenges as we will look at how an idea or discovery can evolve into a fully-fledged large company. There will be speakers from large companies like Novo Nordisk and Lundbeck as well as start-up level and everything in between.

Furthermore there will be plenty of time to network with other students and industry professionals.

During the week our speakers will cover topics such as:
► International Property Rights
► Business Development
► Regulatory Affairs
► Bioentrepreneurship
► Consulting
► Finance
► Venture Capital
► Innovation
► Case solving
► Inspiration and insight from start-up to major company
► Detailed programme will be announced at a later time

Alongside the workshops and talks there will be a case competition developed and run by the Boston Consulting Group and BioInnovation Institute.


Danish Foundation for Entrepreneurship

The Danish Foundation for Entrepreneurship works to ensure that the ability to be innovative is a fundamental element in all educations from primary school to PhD. Innovation and entrepreneurship must to a higher degree be integrated in the educations and become deeply embedded at the educational institutions.

The Danish Foundation for Entrepreneurship allocates funding for the development and further development of education with a focus on innovation and entrepreneurship at all levels of the education system. The Foundation also develops and publishes its own education material, advises on the implementation of entrepreneurship in teaching, and facilitates the cooperation and networking about entrepreneurship education.

The Foundation works as a knowledge centre to diffuse and communicate results from research about entrepreneurship teaching. Through surveys and analyses the Foundation also helps generate new knowledge about the spread and impact of entrepreneurship education in Denmark.

BioInnovation Institute

BII offers entrepreneurially-minded researchers or anyone with a research-based idea help to bring interdisciplinary ideas to life and research to market. We offer state-of-the-art facilities and various funding opportunities, as well as partnerships and programs with technical, scientific and commercial experts.

Our main focus is health tech, bio-industrials and therapeutics. We envision that strong collaborations, a passion for science, and an open mind will foster research-based innovation and viable start-ups. BII does not work for profit but for the benefit of human welfare and society around the globe.

BII is a Novo Nordisk Foundation initiative. In the first three years of operation, until the end of 2020, BII has been granted DKK 392 million. After this establishment phase has been evaluated, the Novo Nordisk Foundation’s Board of Directors will decide whether to establish BII as an independent foundation and grant funding for the next seven years of operation.

Venture Cup

Venture Cup Denmark is an association of all the Danish universities (except RUC). We work to promote and showcase entrepreneurship among university students, and help eliminate the gap between the academic world and the business community. A pioneer in the field, Venture Cup has been founded in 2000 as one of the first entrepreneurial organisations in the country.

We host two national startup competitions annually, a University Startup World Cup with teams from all over the world and access to a large network of Venture Cup Experts. Early 2018 we have launched the program Nordic HealthTech Talents with the support of Novo Nordisk Foundation.

Besides that we’re always trying to be in the loop and cooperate with companies and stakeholders if we believe it supports our mission of inspiring and showcasing the university students.

Lundbeckfonden Ventures

Lundbeckfonden Ventures is an evergreen venture fund investing internationally in life science companies. Our focus is primarily projects and companies with development candidates close to or in clinical development. We are particularly interested in speciality pharma product opportunities and in technology platforms that have demonstrated their value in generating development candidates.

About us
Since 2009, we have invested in 31 companies in USA and Europe and have an active portfolio of around 20 companies representing a broad spectrum of therapeutic fields. Annually we invest 350 to 400 million Danish kroner.
We work internationally and as lead investor when investing in Europe. We are determined to add value to our investments and will involve ourselves actively in our portfolio companies and work in close collaboration with their management and boards.


We are passionate people building winning teams with our customers. With deep roots in the pharmaceutical industry, we supply services that meet the highest requirements for quality, security and standardization. Read more about our quality and security​.

NNIT​ is one of Denmark’s leading consultancies in IT development, implementation and operations. For over a decade, we have applied the latest advances in technology to make software development, business processes and communication significantly more effective. Read about our values and culture​​​.

​NNIT’s service offerings include advising, building, implementing, managing and supporting IT solutions and operating IT systems for customers. ​In 2018 our revenue stood at DKK 3 billion. Read more about our life sciences services​ and customers​​.

Today, NNIT has approximately 3,300 employees – of which approximately half work outside the borders of ​Denmark – in China​​, the Czech Republic​, the ​Philippines​, Switzerland​, Germany and in the US. Read about our ​history here.​​​

Dawn Health

Dawn provides life-changing digital health therapies driving improved patient outcomes beyond the pill. We deliver strategic consulting and develop innovative digital health solutions in close collaboration with the pharmaceutical, medical device, and biotech industries.
We envision a connected healthcare industry that efficienctly develops individualized treatments for patients and empowers practitioners to choose and manage the right treatments.

As an ISO13485:2016 certified developer of regulated digital health products, Dawn delivers value throughout the entire project lifecycle from concept and launch, to ongoing maintenance, support, and user acquisition.


We are the CRISPR Microbiome Company

Precision killing of bacteria has the impact to revolutionise the management of untreatable and difficult-to-treat infections as well as complex diseases directly impacted by the human microbiota.

Our mission is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future.

Boston Consulting Group

The Boston Consulting Group (BCG) is a global management consulting firm and the world’s leading advisor on business strategy. Now in our sixth decade, we continue not only to grow but also to embody the same timeless sense of purpose and the constant call for renewal that our founder Bruce Henderson instilled at our inception. Our mission is clear. We go deep to unlock insight and have the courage to act. We bring the right people together to challenge established thinking and drive transformation. We work with our clients to build the capabilities that enable organizations to achieve sustainable advantage. We are shaping the future.

Novo Nordisk Regulatory Affairs

In Novo Nordisk, Regulatory Affairs secure the approval of new multi-billion dollar products and drug indications, making it possible for the company to bring innovative products to patients. The department stand at the centre of project planning and execution from the earliest stages of drug development all the way through life cycle management. A close collaboration with scientists to ensure new ideas will turn into successful products, thus a large part of Regulatory Affairs is based on the ability to understand the science behind.
The Regulatory Affairs graduate programme has been designed to develop top talents into becoming future leaders within this area. The Graduate Program is a two-year program consisting of three department rotations in which one of these will take place in one of the global affiliates. The Programme is open to applicants from all over the world who have recently acquired a degree from the life sciences such as pharmacy, chemical engineering, biology, biotechnology biomedicine or a related field.


HØIBERG is a full service patent law firm located in Denmark, which is providing services within the fields of Intellectual Property Rights (IPR), including patents, designs, innovation management, technology transfer and business development. HØIBERG provides expert IPR knowledge in the fields ranging from biotech, medtech, nanotech, chemistry and cleantech to software, electronics and mechanics.

LEO Pharma

Leo Pharma is an independent, research-based pharmaceutical company. The company develops, manufactures and markets pharmaceutical drugs to dermatologic and thrombotic patients in more than 100 countries globally.

To realise their vision of becoming the preferred dermatology care partner improving people’s lives around the world, they are expanding into new regions and markets, reaching more patients and societies with drugs and therapies that address unmet medical needs.

Leo Pharma has its own sales forces in 61 countries and employs around 5,000 employees worldwide. The company is headquartered in Denmark and is wholly owned by the Leo Foundation.

Chr. Hansen

Chr. Hansen is a global bioscience company that develops natural solutions for the food, nutritional, pharmaceutical and agricultural industries.

We develop and produce cultures, enzymes, probiotics and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements, animal feed, and plant protection. Our product innovation is based on around 40,000 microbial strains – we like to refer to them as “good bacteria.”

Our solutions enable food manufacturers to produce more with less – while also reducing the use of chemicals and other synthetic additives – which makes our products highly relevant in today’s world. We have been delivering value to our partners – and, ultimately, end consumers worldwide – for more than 145 years. We are proud that more than 1 billion people consume products containing our natural ingredients every day.


Horten is a full-service law firm with more than 60 years’ experience and 320 employees, which is specialised within sectors characterised by strict regulation or where technological development and innovative approaches are fundamental – such as energy and supply, Life Science and Healthcare, IT, technology and media as well as the public sector.
We use our special expertise within regulated areas proactively to solve complex problems and think innovatively, be it new energy forms, advanced technology or cooperation between public and private parties.


Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare. Our business includes Ostomy Care, Continence Care, Wound & Skin Care and Interventional Urology. We operate globally, and our organisation is about 11,000 people strong

Forward Pharma

Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on Biogen’s net sales of Tecfidera® or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the ‘355 Patent Opposition Proceeding, including any appeal thereto.


Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases – we call this Progress in Mind.

Despite the challenges, Lundbeck remains steadfast in our commitment to deliver innovation that patients need. We work tirelessly to advance neuroscience, develop new and innovative treatments, and support patient communities – all with the aim of restoring brain health and transforming the lives of the millions of people living with a brain disease. Not only does the burden of brain diseases demand action now, it also demands expertise and courage. We know that to get radically different results, we need to pursue radically different approaches.

Our approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing, and sales. Our pipeline consists of several R&D programs and our products are available in more than 100 countries. We have research centers in Denmark and California and our production facilities are located in Denmark, France, and Italy.


PANCRYOS is a spin-out arising from the Novo Nordisk Foundation Center for Stem Cell Biology (DanStem) at the University of Copenhagen. The company is aiming to develop a next generation stem cell derived allogeneic cell therapy (PanINSULA™) for type 1 diabetes. Based on novel IP, PANCRYOS will – for the first time – enable the definitive safety and large scale manufacturing of insulin cells for therapeutic use. PANCRYOS is in the pre-clinical stage of development and is addressing cost effective scalability and manufacturing of the cell therapy early on to ensure successful commercialization.

PANCRYOS is founded by stem cell biologists Assistant Professor Jacqueline Ameri and Professor Henrik Semb who have assembled a team of highly experienced business advisors, regulatory consultants, islet transplantation experts and cell manufacturing CMOs with the goal of testing a mature beta cell therapy in a phase I/IIa clinical trial. PANCRYOS is seeking both partners and investors that could support ongoing efforts towards this goal with a long-term vision of a brighter and healthier future for diabetes patients.


We empower people to make informed decisions about their health and lifestyle by unlocking the full potential of personal technology.

Our latest innovative product will help give couples all over the world the ability to improve their chances of becoming pregnant.


Accelerace is one of the world’s top 10 seed accelerators. Since 2008 Accelerace has spotted, trained and invested in more than 500 of the most promising Danish and international startups and growth companies. 88% of the companies are still on the market today.

As part of the national Scale-up Denmark initiative Accelerace is scaling up startups within tech, foodtech, cleantech, life sciences and welfare technologies through guidance and mentoring from skilled serial entrepreneurs, camps and network.

Accelerace has invested in more than 69 promising startups, who have been through the Accelerace program and have started partnerships with Maersk, Novo Nordisk Foundation, Arla, Foss, NRGI, Business Lolland-Falster, Bang & Olufsen, SE, Endesa & Enel.

Accelerace is also organizing the Nordic NOME (Nordic Mentor Network for Entrepreneurship) mentor network for life science startups. Reach us at info@accelerace.io


CeBIL is the Centre for Advanced Studies in Biomedical Innovation Law based at the University of Copenhagen, Denmark. The overall aim and ambition of CeBIL is to contribute to the translation of groundbreaking biomedical research into safe, effective, affordable and accessible therapies by analyzing the most significant legal challenges to pharmaceutical innovation and public health from a holistic cross-disciplinary perspective.

The Centre for Advanced studies in Biomedical Innovation Law explores the legal challenges and the rapid developments in the biotechnological area. The centre brings together scholars from the worlds leading research institutions in interdisciplinary collaboration also engaging stakeholders from industry, government and civil society.


Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125 000 people of more than 140 nationalities work at Novartis around the world.

A webform by Podio


Date: 16th – 20th of August, 2021

Location: Somewhere in Copenhagen (TBA)

Entry/Admission requirements: Open for all students, recent graduates, PhD or post-docs within life sciences who is based in Denmark

Application period: 26th of May - 26th of June

We will notify selected applicants within two weeks after application period has ended. 


In order for an application to be eligible you must include the following:

  • CV (PDF)
  • Screenshot of your 16-personality test result (test can be taken HERE). Please note, that we need a screenshot of the TEST RESULT, not just the personality type.
  • 1 page motivational letter, where you address the following:
    • Your motivation for participating in the BioBusiness Summer School
    • What can you bring to the team work, and what do you hope to learn during the week?
    • How does your personality type (result from test) align with yourself, and does it resonate with what you will be bringing to the summer school?

If above criteria are not met your application will be disregarded. 

16-personalities test

In order to ensure the best possible team-formations during the week we are focusing on personality types in this years applications. You can take the test by following this link: 

- Mandatory programme 9-17 every day 
- Lunch will be provided without cost every day
- Casework on Wednesday and Thursday evening
- Optional social evening activities will take place Tuesday and Friday

COVID-19 situation: 

Synapse follows the current COVID-19 recommendations and requirements presented by the Danish government and public health authorities. Therefore, Synapse BioBusiness Summer School 2021 will only be available to students and recent graduates based in Denmark.

To all candidates based outside of Denmark, we kindly ask for your understanding and encourage you to apply for the Synapse BioBusiness Summer School 2022, which hopefully will be held with no restrictions.

Synapse are following regulations and guidelines closely in order to ensure that all safety measures are met during the summer school. The Summer School will be a physical activity this year.

Please address questions to afg@synapse-connect.org

COVID-19 situation in Denmark 

Synapse follows the current COVID-19 recommendations and requirements presented by the Danish government and public health authorities. Therefore, Synapse BioBusiness Summer School 2021 will only be available to students and recent graduates based in Denmark.

To all candidates based outside of Denmark, we kindly ask for your understanding and encourage you to apply for the Synapse BioBusiness Summer School 2022, which hopefully will be held with no restrictions.

Synapse is keeping a close eye on how the current COVID-19 situation develops. Based on the current restrictions, we are carrying on our planning of this year's summer school, and we will make decisions based on the authorities' recommendations and requirements accordingly.